International Contract Research Organization to Implement Leading EDC
Solution and Meet Growing Demand for Medidata Rave
NEW YORK AND LONDON, June 18 /CNW/ - Medidata Solutions, a global
provider of electronic clinical data capture (EDC), management and reporting
solutions, today announced that Chiltern Ltd, a full service contract research
organization (CRO), has signed as a partner through Medidata's ASPire to
Win(TM) Program. With this partnership, Medidata will provide the tools and
training that will enable Chiltern to implement Medidata Rave(R) to manage the
company's global Phase I-IV clinical development and late phase programs.
As an early adopter of EDC, Chiltern provides necessary technical project
management, team training and site level training in support of EDC
implementation and adoption. Chiltern's dedicated EDC services to sponsors
range from pilot programs to support of enterprise-level implementation. The
company is looking to expand its service offerings, and after a review of the
leading EDC vendors, Chiltern selected Medidata Rave.
"We selected Medidata Rave since it is the leading EDC solution for ease
of use and implementation. Rave has received an outstanding response from our
users," said Glenn Kerkhof, Chiltern's Chief Executive Officer. "We felt
Medidata was an ideal partner because of our common commitment to quality and
compliance to regulatory expectations, globally."
Medidata's ASPire to Win Program is a non-exclusive application service
provider (ASP) partnership and business model. The program will allow Chiltern
to meet sponsor demand for Medidata Rave and offer the platform in-house. As a
result, Chiltern will be able to create new services revenue around the
implementation of this industry-leading technology.
Chiltern will leverage Medidata's ASPire to Win Program to build on the
company's established presence as an EDC provider. The Rave certification will
allow Chiltern's EDC Solutions Group to continue to expand their offerings for
sponsors. This group currently provides advice and support for all EDC trials
within Chiltern and assists with site and sponsor training as needed.
"Along with a progressive view of clinical technology, Chiltern has an
impressive client base and a broad global reach," said Tarek Sherif, CEO of
Medidata Solutions. "Through our ASPire to Win Program, Chiltern will be able
to quickly realize the benefits and ROI that Medidata Rave brings and build
upon its existing position in the CRO market."
Established in 1982, Chiltern is a leading global contract research
organization with extensive experience of running and staffing international
Phase I to Phase IV clinical trials across a broad therapeutic range for a
wide variety of clients. Chiltern employs more than 1000 people with 18
offices across the United States, Europe and India. Chiltern provides
development services including Early Phase, Global Clinical Development, Late
Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions.
About Medidata Solutions Worldwide
Medidata Solutions helps the world's leading pharmaceutical,
biotechnology, medical device and research organizations maximize the value of
their clinical research investments. Innovative process design, technology and
services streamline clinical trials by providing early visibility to reliable
clinical data - the lifeblood of every research organization. Working with
companies and institutions both large and small, Medidata Solutions helps
clinical researchers safely accelerate the process of bringing life-enhancing
treatments to market - on six continents and in more than 80 countries.
Medidata Solutions brings significant value to its broad client base with deep
clinical experience and expertise in more than 20 therapeutic areas, projects
in Phase I, II, III, IV, registries and surveillance, and studies with
thousands of investigators and tens-of-thousands of subjects. For more
information, please visit www.mdsol.com.
For further information:
For further information: Lois Paul & Partners Susan Lombardo,
781-782-5767 Susan_Lombardo@lpp.com or Chiltern Ltd. Catherine Lemercier,